W Cory Johnston1, Helena M Hoen1, Maria A Cassera2, Pippa H Newell2, Chet W Hammill2, Paul D Hansen3, Ronald F Wolf2. 1. Hepatobiliary and Pancreatic Surgery Program, Providence Portland Medical Center, Portland, OR, United States. 2. Hepatobiliary and Pancreatic Surgery Program, Providence Portland Medical Center, Portland, OR, United States; Gastrointestinal and Minimally Invasive Surgery Division, The Oregon Clinic, Portland, OR, United States. 3. Hepatobiliary and Pancreatic Surgery Program, Providence Portland Medical Center, Portland, OR, United States; Gastrointestinal and Minimally Invasive Surgery Division, The Oregon Clinic, Portland, OR, United States. Electronic address: phansen@orclinic.com.
Abstract
BACKGROUND: Total pancreatectomy is infrequently performed for pancreatic cancer. Perceived operative mortality and questionable survival benefit deter many surgeons. Clinical outcomes, described in single-center series, remain largely unknown. METHODS: The National Cancer Database was queried for cases of pancreatic ductal adenocarcinoma undergoing total pancreatectomy (1998-2011). Univariate survival analyses were performed for 21 variables: demographic (8), tumor characteristics (5), surgery outcomes (6), and adjuvant therapy (2). The Log-rank test of differences in Kaplan-Meier survival curves was used for categorical variables. Variables with p < 0.05 were included in a multivariate analysis. Cox proportional hazards regression was used to analyze continuous variables and multivariate models. RESULTS: 2582 patients with staging and survival data made up the study population. 30-day mortality was 5.5%. Median overall survival was 15 months, with 1, 3, and 5-year survival rates of 60%, 22%, and 13%, respectively. Age, facility type, tumor size and grade, lymph node positivity, margin positivity, and adjuvant therapy significantly impacted survival in multivariate analysis. CONCLUSION: Although total pancreatectomy is a reasonable option for selected patients with pancreatic ductal adenocarcinoma, survival of the entire group is limited. Operative mortality is improved from prior reports. Greater survival benefits were seen in younger patients with smaller, node negative tumors resected with negative margins in academic research centers.
BACKGROUND: Total pancreatectomy is infrequently performed for pancreatic cancer. Perceived operative mortality and questionable survival benefit deter many surgeons. Clinical outcomes, described in single-center series, remain largely unknown. METHODS: The National Cancer Database was queried for cases of pancreatic ductal adenocarcinoma undergoing total pancreatectomy (1998-2011). Univariate survival analyses were performed for 21 variables: demographic (8), tumor characteristics (5), surgery outcomes (6), and adjuvant therapy (2). The Log-rank test of differences in Kaplan-Meier survival curves was used for categorical variables. Variables with p < 0.05 were included in a multivariate analysis. Cox proportional hazards regression was used to analyze continuous variables and multivariate models. RESULTS: 2582 patients with staging and survival data made up the study population. 30-day mortality was 5.5%. Median overall survival was 15 months, with 1, 3, and 5-year survival rates of 60%, 22%, and 13%, respectively. Age, facility type, tumor size and grade, lymph node positivity, margin positivity, and adjuvant therapy significantly impacted survival in multivariate analysis. CONCLUSION: Although total pancreatectomy is a reasonable option for selected patients with pancreatic ductal adenocarcinoma, survival of the entire group is limited. Operative mortality is improved from prior reports. Greater survival benefits were seen in younger patients with smaller, node negative tumors resected with negative margins in academic research centers.
Authors: J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils Journal: Ann Surg Date: 1999-12 Impact factor: 12.969
Authors: Michael D'Angelica; Murray F Brennan; Arief A Suriawinata; David Klimstra; Kevin C Conlon Journal: Ann Surg Date: 2004-03 Impact factor: 12.969
Authors: Stefan Heinrich; Markus Schäfer; Achim Weber; Thomas F Hany; Ujwal Bhure; Bernhard C Pestalozzi; Pierre-Alain Clavien Journal: Ann Surg Date: 2008-12 Impact factor: 12.969
Authors: Chandrajit P Raut; Karen R Cleary; Gregg A Staerkel; James L Abbruzzese; Robert A Wolff; Jeffrey H Lee; Jean-Nicolas Vauthey; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans Journal: Ann Surg Oncol Date: 2006-03-07 Impact factor: 5.344
Authors: Hari Nathan; Christopher L Wolfgang; Barish H Edil; Michael A Choti; Joseph M Herman; Richard D Schulick; John L Cameron; Timothy M Pawlik Journal: J Surg Oncol Date: 2009-02-01 Impact factor: 3.454
Authors: Riccardo Casadei; Claudio Ricci; Giovanni Taffurelli; Anna Guariniello; Anthony Di Gioia; Mariacristina Di Marco; Nico Pagano; Carla Serra; Lucia Calculli; Donatella Santini; Francesco Minni Journal: J Gastrointest Surg Date: 2016-07-14 Impact factor: 3.452
Authors: M J Passeri; E H Baker; I A Siddiqui; M A Templin; J B Martinie; D Vrochides; D A Iannitti Journal: Curr Oncol Date: 2019-06-01 Impact factor: 3.677
Authors: Bowen Qi; Ayrianne J Crawford; Nicholas E Wojtynek; Megan B Holmes; Joshua J Souchek; Graca Almeida-Porada; Quan P Ly; Samuel M Cohen; Michael A Hollingsworth; Aaron M Mohs Journal: Nanomedicine Date: 2018-01-09 Impact factor: 5.307
Authors: Wenchuan Wu; Rebecca Dodson; Martin A Makary; Matthew J Weiss; Kenzo Hirose; John L Cameron; Nita Ahuja; Timothy M Pawlik; Christopher L Wolfgang; Jin He Journal: World J Surg Date: 2016-10 Impact factor: 3.352
Authors: Hazem M Zakaria; John A Stauffer; Massimo Raimondo; Timothy A Woodward; Michael B Wallace; Horacio J Asbun Journal: World J Gastrointest Surg Date: 2016-09-27
Authors: Dong S; Wang L; Guo Y B; Ying H F; Shen X H; Meng Z Q; Chen Hao; Chen Q W; Li Z S Journal: World J Surg Oncol Date: 2017-07-03 Impact factor: 2.754